The short version of RP-HPLC fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-26. Anything still debated is marked as such rather than presented as settled.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
In Japan, a common lunch in the summer months is hiyayakko (冷奴), silken or firm East Asian tofu served with freshly grated ginger, green onions, or katsuobushi shavings with soy sauce. In the winter, tofu is frequently eaten as yudofu, which is simmered in a clay pot in kombu dashi, with vegetables such as Chinese cabbage or green onion. Deep fried tofu is called atsuage (厚揚げ) or namaage (生揚げ) in Japan. The thinner variety called aburaage (油揚げ), develops a tofu pouch often used for inarizushi. In Japan, cubes of lightly coated and fried tofu topped with a kombu dashi-based sauce are called agedashi dōfu (揚げ出し豆腐). Soft tofu that has been thinly sliced and deep fried, known as aburage in Japan, is commonly blanched, seasoned with soy sauce and mirin and served in dishes such as kitsune udon. In Gifu Prefecture, there is a local specialty called komo-dofu, which consists of tofu that has been wrapped in a komo, or mat of woven straw, which leaves its imprint on the exterior. The wrapped tofu is then boiled in soup stock. Voids within the tofu develop during the boiling process, allowing the soup stock flavor to penetrate and giving it a distinctive porous appearance. Japanese miso soup is frequently made with tofu.
== Awards and honors == 2017, "From Discovery to Precision Medicine: Mass Spectrometry Through the Years and Beyond" at Pittcon 2017, a session focused on the contributions of Robert E. Finnigan 2008, Selected for "Legends of Environmental Chemistry" by American Chemical Society, ACS annual meeting, New York 1999, Instrumentation Hall of Fame (Charter Member) by Pittcon, American Chemical Society and Chemical Heritage Foundation 1994, Selected as a Pioneer in Development of Analytical Instrumentation by Pittsburgh Conference (Pittcon) and American Chemical Society 1980, Distinguished Service in Engineering, College of Engineering, University of Illinois 1975, Distinguished Alumni Award, Electrical and Computer Engineering Department, University of Illinois
The sodium-iodide symporter transports two sodium ions across the basement membrane of the follicular cells along with an iodine ion. This is a secondary active transporter that utilises the concentration gradient of Na+ to move I− against its concentration gradient. I− is moved across the apical membrane into the colloid of the follicle. Thyroperoxidase oxidises I− to form the I radical. The thyroperoxidase iodinates the tyrosyl residues of the thyroglobulin within the colloid. The thyroglobulin was synthesised in the ER of the follicular cell and secreted into the colloid. Thyroid-stimulating hormone (TSH) released from the anterior pituitary gland binds the TSH receptor (a Gs protein-coupled receptor) on the basolateral membrane of the cell and stimulates the endocytosis of the colloid. The endocytosed vesicles fuse with the lysosomes of the follicular cell. The lysosomal enzymes cleave the T4 from the iodinated thyroglobulin. These vesicles are then exocytosed, releasing the thyroid hormones.
==== Misuse of prescription medication ==== Misused prescription medicine, such as opioids, can lead to heroin use and dependence. The number of death from illegal opioid overdose follows the increasing number of death caused by prescription opioid overdoses. Prescription opioids are relatively easy to obtain. This may ultimately lead to heroin injection because heroin is cheaper than prescribed pills.
Sources: en.wikipedia.org
== Pharmacokinetics == Lamivudine is well absorbed in the body and distributes widely into the extravascular space. Oral bioavailability is >80% and overall metabolism is insignificant where approximately 95% of the drug is found unchanged in the urine. The only known metabolite found in humans is trans-sulfoxide. The half-life of lamivudine is 10 to 15 hours and binds poorly to plasma proteins. Zidovudine is also well absorbed in the body and penetrates into the cerebrospinal fluid. Oral bioavailability is 75% and primarily metabolized by the liver by glucuronidation. The primary metabolite is GZDV, an inactive metabolite produced after first pass metabolism. The half-life of zidovudine is 0.5 to 3 hours and binds poorly to plasma proteins. Lamivudine and zidovudine are not extensively metabolized by CYP450 liver enzymes.
16 August – A university reports the release of 'Quad-SDK' which may be the first open source full-stack software for large agile four-legged robots, compatible with the ROS. 17 August A report by Global Forest Watch, using new data, concludes that the amount of tree cover being burned has nearly doubled in the past 20 years. The Nadir crater, likely the result of a second, smaller asteroid that struck around the same time as the Chicxulub impact, is identified and described by researchers. Geologists warn that the world is "woefully underprepared" for a massive volcanic eruption. They estimate a one-in-six chance of a magnitude seven explosion in the next one hundred years. Researchers report the development of floating artificial leaves for light-driven hydrogen and syngas fuel production. The lightweight, flexible devices are scalable and can float on water similar to lotus leaves.
This is a timeline of women in science, spanning from ancient history up to the 21st century. While the timeline primarily focuses on women involved with natural sciences such as astronomy, biology, chemistry, and physics, it also includes women from the social sciences (e.g. sociology, psychology), and the formal sciences (e.g. mathematics, computer science), as well as notable science educators and medical scientists. The chronological events listed in the timeline relate to both scientific achievements and gender equality within the sciences.
Costunolide synthase (EC 1.14.14.150) is an enzyme with systematic name germacra-1(10),4,11(13)-trien-12-oate,NADPH:oxygen oxidoreductase (6alpha-hydroxylating). This enzyme catalyses the following chemical reaction
== Features == The purpose of ModDB is to list the mods, files, tutorials and information of any games that are capable of being modded with user-made content. The website allows users to create pages for mods, upload screenshots and files, publish news, and request help from the community. Scott's intentions, from the beginning, were to get the community heavily involved in the creation and development of the website. To this end, the most active members were chosen as moderators and administrators. The core staff generally remain the same, while lower positions are heavily rotated among trainee moderators, and administrator candidates. ModDB's terms of use prohibit certain types of content, including pornographic, defamatory, and obscene content, as well as material that incites crime or hatred, violates intellectual property law under the terms of the copyright law of Australia and the Digital Millennium Copyright Act, or otherwise "brings [the website] into disrepute." Nevertheless, the website received mainstream media attention when in early 2011 it hosted School Shooter: North American Tour 2012, a Half-Life 2 mod. The mod's premise led to a number complaints accusing the website of being involved in the project, prompting the website to shut it down in March.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.